Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43801   clinical trials with a EudraCT protocol, of which   7258   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-001810-13
    Sponsor's Protocol Code Number:GSN000350
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-11-05
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-001810-13
    A.3Full title of the trial
    TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
    TRANSFORM: sperimentazione adattiva di fase 2b/3, di 52 settimane, randomizzata, controllata con placebo, in doppio cieco su setanaxib con una fase di estensione di 52 settimane in pazienti con colangite biliare primaria (CBP) e rigidità epatica elevata
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with PBC and Elevated Liver Stiffness
    Sperimentazione di fase 2b/3 su setanaxib con una fase di estensione di 52 settimane in pazienti con colangite biliare primitiva (CBP) e rigidità epatica elevata
    A.3.2Name or abbreviated title of the trial where available
    TRANSFORM
    TRANSFORM
    A.4.1Sponsor's protocol code numberGSN000350
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGenkyotex Suisse SA
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCalliditas Therapeuthics AB
    B.4.2CountrySweden
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPRA Health Sciences
    B.5.2Functional name of contact pointBenedicte Moal Rowland
    B.5.3 Address:
    B.5.3.1Street Address500 South Oak Way, Green Park
    B.5.3.2Town/ cityReading
    B.5.3.3Post codeRG2 6AD
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number+441189181100
    B.5.6E-mailrowlandbenedicte@prahs.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/20/2387
    D.3 Description of the IMP
    D.3.1Product nameSETANAXIB
    D.3.2Product code [GKT137831]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSetanaxib
    D.3.9.1CAS number 1218942-37-0
    D.3.9.2Current sponsor codeGKT137831
    D.3.9.4EV Substance CodeSUB195304
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number400
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
    Colangite biliare primitiva (PBC) ed elevata rigidità epatica
    E.1.1.1Medical condition in easily understood language
    Liver disease caused by autoimmune attack on the small to medium bile ducts
    Malattia del fegato causata da attacco autoimmune ai piccoli e medi condotti biliari
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level PT
    E.1.2Classification code 10080429
    E.1.2Term Primary biliary cholangitis
    E.1.2System Organ Class 10019805 - Hepatobiliary disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the effect of setanaxib on biochemical response at Week 52 in patients with PBC and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA)
    Valutare l’effetto di setanaxib sulla risposta biochimica alla Settimana 52 in pazienti con CBP ed elevata rigidità epatica e intolleranza o risposta inadeguata all’acido ursodesossicolico (UDCA)
    E.2.2Secondary objectives of the trial
    - To evaluate the effect of setanaxib on liver stiffness at Week 52
    - To evaluate the effect of setanaxib on fatigue at Week 52
    - To evaluate the effect of setanaxib on pruritus at Week 52
    - To evaluate the safety and tolerability of setanaxib over a 52 week treatment period
    - To further evaluate the safety and tolerability of setanaxib in patients with PBC and with elevated liver stiffness and intolerance or inadequate response to UDCA (Extension phase)
    - Valutare l'effetto di setanaxib sulla rigidità epatica alla settimana 52
    - Valutare l'effetto di setanaxib sull'affaticamento alla settimana 52
    - Valutare l'effetto di setanaxib sul prurito alla settimana 52
    - Valutare la sicurezza e la tollerabilità di setanaxib in un periodo di trattamento di 52 settimane
    - Valutare ulteriormente la sicurezza e la tollerabilità di setanaxib in pazienti con PBC e con elevata rigidità epatica e intolleranza o risposta inadeguata all'UDCA (fase di estensione)
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male or female patient aged =18 years, inclusive at the time of informed consent.
    2. Willing and able to give written informed consent and to comply with the requirements of the study.
    3. Definite or probable PBC diagnosis as demonstrated by the presence of =2 of the following 3 diagnostic factors:
    a. Documented history of elevated ALP levels =1.67×ULN of the local reference range
    b. Positive AMA titer or, if AMA negative or in low titer (<1:80), positive PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components [PDC-E2, 2-oxo-glutaric acid dehydrogenase complex])
    c. Liver biopsy consistent with PBC.
    4. Serum ALP =1.67×ULN at Screening. One repeat blood sampling (with analysis by the central laboratory) can be performed at the discretion of the Investigator at Screening Visit 2 for patients who do not meet this inclusion criterion at Screening Visit 1. If this inclusion criterion is then met at Screening Visit 2, the patient may be eligible for the study.
    5. Liver stiffness measured by transient elastography (FibroScan®) of = 8.8 kPa at Screening and at Baseline (a minimum of 10 valid readings, with at least a 70% success rate and an interquartile range of =30% of the median value, are taken with the results expressed in kilopascals [kPa]).
    6. UDCA prescriptional dose use for the past 6 months (at a stable dose for >3 months prior to Screening) OR intolerant to UDCA (last dose of UDCA >3 months prior to Screening).
    7. For patients receiving OCA, fenofibrate, or bezafibrate treatment for at least 6 months and stable dose for >3 months prior to Screening.
    8. For patients intolerant to OCA, OCA must have been discontinued >3 months prior to Screening.
    9. For patients previously treated with bezafibrate or fenofibrate, these agents must have been be discontinued >3 months prior to Screening.
    10. Female patients of childbearing potential must use a highly effective method of contraception to prevent pregnancy for =4 weeks before Randomization and must agree to continue strict contraception up to 90 days after the last dose of IMP.
    a. For the purposes of this trial, women of childbearing potential are defined as "All female patients after menarche unless they are postmenopausal for at least 2 years or are surgically sterile."
    b. For female patients =55 years of age who are considered postmenopausal and who are not on concomitant estrogen replacement therapy, confirmation of postmenopausal status will be required with follicle stimulating hormone (FSH) test results in the postmenopausal range for age at Screening.
    c. Highly effective contraception is defined as use of 2 barrier methods (eg, female diaphragm and male condoms) or use of at least 1 barrier
    method in combination with spermicide, an intrauterine device or hormonal contraceptives (eg, implant or oral).
    11. Female patients of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline/Randomization before dosing.
    12. Male patients with female partners of childbearing potential must be willing to use a condom and require their partner to use an additional form of adequate contraception as approved by the Investigator, such as an established form of hormonal contraceptive, a diaphragm or cervical/vault cap, or intrauterine device. This requirement begins at the time of informed consent and ends 90 days after receiving the last dose of IMP.
    13. Male patients must be willing not to donate sperm, and female study participants must be willing not to donate eggs, from Baseline until 90 days after the last dose of IMP.
    1. Pazienti di sesso maschile o femminile di età =18 anni (inclusi) al consenso informato
    2. Volontà e capacità di dare il proprio consenso informato scritto e di rispettare i requisiti dello studio
    3. Diagnosi definitiva o probabile di CBP dimostrata dalla presenza di =2 dei 3 fattori diagnostici seguenti:
    a. Anamnesi documentata di livelli elevati di ALP =1,67xULN dell’intervallo di riferimento locale
    b. Titolo di anticorpi AMA positivo o, se negativo o basso(<1:80), anticorpi CBP-specifici positivi (anti-GP210 e/o anti-SP100 e/o anticorpi contro i principali componenti di M2 [PDC-E2, complesso della 2-ossoglutarato deidrogenasi])
    c. Biopsia epatica coerente con CBP
    4. ALP sierica=1,67 x ULN allo screening
    Il prelievo di un campione di sangue (con analisi da parte del laboratorio centrale) può essere eseguito a discrezione del PI alla visita di screening 2 per pazienti che non soddisfano questo criterio di inclusione alla visita di screening 1. Se questo criterio di inclusione viene soddisfatto alla visita di screening 2, paziente è idoneo.
    5. Rigidità epatica misurata mediante elastografia transitoria (FibroScan®)=8,8 kPa allo screening e basale (minimo 10 letture valide, con tasso di successo di almeno 70% e un intervallo interquartile =30% del valore mediano, con risultati in kilopascal kPa)
    6. Dose prescritta di UDCA negli ultimi 6 mesi (a una dose stabile per >3mesi prima dello screening) OPPURE intolleranza a UDCA (ultima dose di UDCA >3 mesi prima dello screening)
    7. I pazienti che ricevono OCA, fenofibrato o bezafibrato devono aver assunto il trattamento per almeno 6 mesi e a una dose stabile per >3 mesi prima dello screening
    8. Per i pazienti intolleranti all’OCA, l’OCA deve essere stato interrotto >3mesi prima dello screening
    9. Per i pazienti precedentemente trattati con bezafibrato o fenofibrato, questi agenti devono essere stati interrotti >3mesi prima dello screening
    10. Pazienti femminili in età fertile devono utilizzare un metodo contraccettivo altamente efficace per prevenire la gravidanza per =4 settimane prima della randomizzazione e accettare di continuare a utilizzare un metodo contraccettivo rigoroso fino a 90 giorni dopo l’ultima dose di IMP
    a. Ai fini dello studio, donne in età fertile sono definite come “tutte le pazienti di sesso femminile dopo il menarca, a meno che non siano in post-menopausa da almeno 2 anni o siano chirurgicamente sterili”
    b. Per le pazienti di sesso femminile di età =55 anni che sono considerate post-menopausa e che non sono sottoposte a terapia sostitutiva concomitante con estrogeni, sarà richiesta la conferma dello stato di post-menopausa con i risultati del test dell’ormone follicolo-stimolante (FSH) nell’intervallo della post-menopausa per l’età allo screening
    c. Per contraccezione altamente efficace si intende l’uso di 2 metodi barriera (ad es. diaframma femminile e preservativi maschili) o l’uso di almeno 1 metodo barriera in combinazione con spermicida, un dispositivo intrauterino o contraccettivi ormonali (ad es impianto o orale)
    11. Le pazienti di sesso femminile in età fertile devono presentare un test di gravidanza sul siero negativo allo screening e un test di gravidanza sulle urine negativo al basale/alla randomizzazione prima della somministrazione
    12. I pazienti di sesso maschile con compagne in età fertile devono essere disposti a utilizzare un preservativo e richiedere alla propria compagna di utilizzare una forma aggiuntiva di contraccezione adeguata approvata dal PI, come una forma consolidata di contraccettivo ormonale, un diaframma o un cappuccio cervicale/pessario o un dispositivo intrauterino. Questo requisito inizia al momento del consenso informato e termina 90 giorni dopo aver ricevuto l’ultima dose di IMP
    13. I pazienti maschili devono essere disposti a non donare sperma e le partecipanti di sesso femminile devono essere disposte a non donare ovuli dal basale fino a 90 giorni dopo l’ultima dose di IMP
    E.4Principal exclusion criteria
    1. A positive pregnancy test or breastfeeding for female patients.
    2. Any historical or current hepatic decompensation event defined as variceal/portal hypertension bleed and/or hepatic encephalopathy, spontaneous bacterial peritonitis, ascites requiring treatment, or liver transplantation list inclusion.
    3. History of liver transplantation, current placement on a liver transplant list or current MELD score of =12 unless the patient is on anticoagulant therapy, or a Child Pugh Score of =6.
    4. Cirrhosis with complications, including history or presence of hepatocellular carcinoma.
    5. Total bilirubin >2×ULN. In case of total bilirubin elevation >ULN the Screening serum albumin must be within the reference range. One repeat blood sampling (with analysis by the central laboratory) can be performed at the discretion of the Investigator at Screening Visit 2 for patients who meet this exclusion criterion at Screening Visit 1. If this exclusion criterion is not met at Screening Visit 2, the patient may be eligible for the study.
    6. Plasma ALT >3×ULN and/or AST >3×ULN. One repeat blood sampling (with analysis by the central laboratory) can be performed at the discretion of the Investigator at Screening Visit 2 for patients who meet this exclusion criterion at Screening Visit 1. If this exclusion criterion is not met at Screening Visit 2, the patient may be eligible for the study.
    7. INR >1.2 unless patient is on anticoagulant therapy.
    8. Estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m2, as calculated by the central laboratory using the chronic kidney disease epidemiology collaboration (CKD EPI) equation.
    9. Thyroid stimulating hormone >ULN at Screening.
    10. Competing etiology for liver disease (eg, hepatitis C [unless effectively cured of hepatitis C, with a sustained virologic response for at least 6 months prior to Screening], active hepatitis B [HBsAg positive], nonalcoholic steatohepatitis [NASH], alcoholic liver disease, autoimmune hepatitis, autoimmune hepatitis PBC overlap syndrome, primary sclerosing cholangitis, Gilbert's Syndrome).
    11. Medical conditions that could cause nonhepatic increases in ALP (eg, Paget's disease).
    12. Known history of HIV infection. If the anti-HIV antibody test is positive, HIV RNA negativity has to be confirmed by the central laboratory.
    13. Surgery (eg, stomach bypass) or medical condition that might significantly affect absorption of medicines (as judged by the Investigator).
    14. Positive urine drug screen (if not due to prescriptional use of a concomitant medication, as confirmed by the Investigator) at Screening.
    15. Patients receiving prohibited medications within 3 months of Screening Visit 1 including oral and systemic corticosteroids (see Section 6.6 for exceptions), colchicine, mycophenolate mofetil, azathioprine, methotrexate, sulfasalazine, leflunomide, cyclophosphamide, valproate, isoniazid, or nitrofurantoin. Any biologic agent within 12 weeks or 5 half lives prior to Screening, whichever is longer. In the case of rituximab, use within 168 days (24 weeks) of Screening is exclusionary. See the complete list of prohibited medications in Section 6.6.
    16. Treatment with any investigational agent within 12 weeks of Screening Visit 1 or 5 half-lives of the IMP (if known) (whichever is longer) or current enrollment in an interventional clinical trial.
    [...] For a complete list of exclusion criteria please refer to the protocol.
    1. Un test di gravidanza positivo o allattamento per le pazienti di sesso femminile.
    2. Qualsiasi evento di scompenso epatico precedente o in corso definito come emorragia da ipertensione variceale/portale e/o encefalopatia epatica, peritonite batterica spontanea e ascite che richiedono trattamento, oppure inclusione nell’elenco dei trapianti di fegato.
    3. Anamnesi di trapianto di fegato, attuale inclusione in un elenco dei trapianti di fegato o punteggio MELD attuale =12, a meno che il paziente non sia in terapia anticoagulante, oppure punteggio Child Pugh =6.
    4. Cirrosi con complicanze, compresa anamnesi o presenza di carcinoma epatocellulare.
    5. Bilirubina totale >2 volte l’ULN. In caso di aumento della bilirubina totale >ULN, l’albumina sierica allo screening deve rientrare nell’intervallo di riferimento.
    Il prelievo di un campione di sangue (con analisi da parte del laboratorio centrale) può essere eseguito a discrezione dello sperimentatore alla visita di screening 2 per i pazienti che soddisfano questo criterio di esclusione alla visita di screening 1. Se questo criterio di esclusione non viene soddisfatto alla visita di screening 2, il paziente può essere idoneo allo studio.
    6. ALT plasmatico >3 volte l’ULN e/o AST >3 volte l’ULN.
    Il prelievo di un campione di sangue (con analisi da parte del laboratorio centrale) può essere eseguito a discrezione dello sperimentatore alla visita di screening 2 per i pazienti che soddisfano questo criterio di esclusione alla visita di screening 1. Se questo criterio di esclusione non viene soddisfatto alla visita di screening 2, il paziente può essere idoneo allo studio.
    7. INR >1,2, a meno che il paziente non sia in terapia anticoagulante.
    8. Velocità di filtrazione glomerulare stimata (eGFR) inferiore a 60 ml/min/1,73 m2, calcolata dal laboratorio centrale utilizzando l’equazione della Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
    9. Ormone tireostimolante >ULN allo screening.
    10. Eziologia competitiva per malattia epatica (ad es., epatite C [a meno che non sia stata curata efficacemente, con una risposta virologica sostenuta per almeno 6 mesi prima dello screening], epatite B attiva [positività a HBsAg], steatoepatite non alcolica [NASH], epatopatia alcolica, epatite autoimmune, sindrome da sovrapposizione epatite autoimmune/CBP, colangite sclerosante primaria, sindrome di Gilbert).
    11. Condizioni mediche che potrebbero causare aumenti non epatici dell’ALP (ad es., malattia di Paget).
    12. Anamnesi nota di infezione da HIV. Se il test degli anticorpi anti-HIV è positivo, la negatività all’RNA dell’HIV deve essere confermata dal laboratorio centrale.
    13. Intervento chirurgico (ad es., bypass gastrico) o condizione medica che potrebbe influire significativamente sull’assorbimento dei farmaci (secondo il giudizio dello sperimentatore).
    14. Positività al test tossicologico sulle urine (se non dovuto all’uso su prescrizione di un farmaco concomitante, come confermato dallo sperimentatore) allo screening.
    15. Pazienti che ricevono farmaci proibiti entro 3 mesi dalla visita di screening 1, compresi i corticosteroidi orali e sistemici (vedere la Sezione 6.6 per le eccezioni), colchicina, micofenolato mofetile, azatioprina, metotrexato, sulfasalazina, leflunomide, ciclofosfamide, valproato, isoniazide o nitrofurantoina. Qualsiasi agente biologico nelle 12 settimane o nelle 5 emivite precedenti lo screening, a seconda di quale sia il periodo più lungo. In caso di rituximab, l’utilizzo entro 168 giorni (24 settimane) dallo screening è motivo di esclusione. Vedere l’elenco completo dei farmaci proibiti nella Sezione 6.6.
    16. Trattamento con qualsiasi agente sperimentale nelle 12 settimane precedenti la visita di screening 1 o 5 emivite dell’IMP (se noto) (a seconda di quale sia il periodo più lungo) o attuale arruolamento in una sperimentazione clinica interventistica.
    [...] Per un elenco completo dei criteri di esclusione si rimanda al protocollo.
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of patients achieving a biochemical response at Week 52, defined as:
    - Alkaline phosphatase (ALP) reduction to <1.67×upper limit of normal (ULN) and
    - ALP reduction of =15% from Baseline and
    - Total bilirubin =1×ULN
    Percentuale di pazienti che ottengono una risposta biochimica alla Settimana 52, definita come:
    - riduzione della fosfatasi alcalina (ALP) a <1,67 × limite superiore della norma (ULN) e
    - riduzione dell’ALP =15% rispetto al basale e
    - bilirubina totale =1 x ULN.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 52
    Settimana 52
    E.5.2Secondary end point(s)
    - Change in liver stiffness at Week 52 compared to Baseline, as assessed by transient elastography (FibroScan®)
    - Change in fatigue at Week 52 compared to Baseline, as assessed by the PBC-40 item questionnaire (PBC 40) fatigue domain and the fatigue domain of the Patient Reported Outcomes Measurement Information System (PROMIS) 29 questionnaire
    - Change in pruritus at Week 52 compared to Baseline, as assessed by the PBC-40 itch domain, 5 D itch scale, and Pruritus Visual Analogue Scale (VAS) in patients with pruritus at Baseline - Adverse events (AEs). Monitoring for AEs at all visits.
    - AEs of special interest (AESIs):
    Drug induced liver injury (DILI)
    Anemia
    Hypothyroidism
    - Laboratory tests:
    Hematology
    Biochemistry
    Urinalysis
    Thyroid function
    - Vital signs
    - 12-lead electrocardiograms (ECGs): clinically significant abnormalities
    - Variazione della rigidità epatica alla settimana 52 rispetto al basale, valutata mediante elastografia transitoria (FibroScan®)
    - Variazione della fatica alla settimana 52 rispetto al basale, come valutato dal dominio della fatica del questionario PBC-40 (PBC 40) e dal dominio della fatica del questionario del sistema informativo di misurazione dei risultati del paziente (PROMIS) 29
    - Variazione del prurito alla settimana 52 rispetto al basale, come valutato dal dominio del prurito PBC-40, dalla scala del prurito 5 D e dalla scala analogica visiva del prurito (VAS) in pazienti con prurito al basale - Eventi avversi (AE). Monitoraggio degli eventi avversi a tutte le visite.
    - AE di particolare interesse (AESI):
    Danno epatico indotto da farmaci (DILI)
    Anemia
    Ipotiroidismo
    - Test di laboratorio:
    Ematologia
    Biochimica
    Analisi delle urine
    Funzione tiroidea
    - Segni vitali
    - Elettrocardiogrammi (ECG) a 12 derivazioni: anomalie clinicamente significative
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 52
    Settimana 52
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA76
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Israel
    New Zealand
    United States
    Austria
    Belgium
    Denmark
    France
    Germany
    Hungary
    Italy
    Netherlands
    Poland
    Spain
    Sweden
    Switzerland
    United Kingdom
    Czechia
    Greece
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as the date of the last visit or last procedure of the last patient in the study.
    La fine dello studio è definita come la data dell'ultima visita o dell'ultima procedura dell'ultimo paziente nello studio.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months11
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 254
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 64
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state18
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 156
    F.4.2.2In the whole clinical trial 318
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-01-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-01-11
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA